New pill targets rare cancer mutation in early trial

NCT ID NCT06386146

Recruiting now Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene (called Y220C). The trial aims to find a safe dose and see if the drug can shrink tumors. About 144 participants who have already tried at least one other cancer treatment will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAB-30355 (oral drug targeting TP53 Y220C mutation)
What this could lead to: If successful, this could lead to a new targeted treatment option for people with advanced solid tumors that have a specific TP53 mutation.
What could go wrong: This is an early-phase trial (Phase 1/2a) with only 144 participants, so safety and effectiveness are not yet proven. The drug may not shrink tumors or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates